MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$26.77
-0.09 (-0.34%)
▼
5d:
-8.79%
30d:
-12.0%
90d:
-3.91%
HOLD
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 18, 2026
3d
Smart Money Accumulation
MLYS is down 8.4% this week, but smart money is accumulating calls. Top strike: $35 2026-06-18 with 4,227 OI. Call ratio: 64% View Scanner →
Strength: 5.6/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $26.77, which is considered oversold relative to its 30-day fair value range of $26.99 to $29.87.
Technical Outlook: Technically, MLYS is in a strong downtrend. The price is currently testing key support at $26.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $48.50 (+80.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MLYS is in a strong downtrend. The price is currently testing key support at $26.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $48.50 (+80.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.99 -
$29.87
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 80.6% below Wall St target ($48.50)
- CAUTION: Recommendation downgraded due to -8.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$26.99 -
$29.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$26.01
Resistance Level
$30.86
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.84
Wall Street Target
$48.50
(+80.6%)
Share & Embed Analysis
Last updated: May 14, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
David Malcom Rodman
SELL
6348 shares
2026-04-15
David Malcom Rodman
SELL
14058 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$130 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 55 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
